The interleukin-1 (IL-1) antagonist anakinra improves endothelial dysfunction in diabetic animals via attenuation of the proinflammatory enzymes cyclooxygenase(COX) and inducible nitric oxide synthase (iNOS) triggered by diabetes in the vascular wall [10, 11]. The gene discussed is NOS2; the disease is diabetes mellitus.